As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Exclusive-Kennedy Played Key Role in Vaccine Case Against Merck By Dan Levine and Mike Spector (Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against ...

Jan 18 (Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los ...

Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck faces broader industry pressure as vaccine skeptic Robert F. Kennedy Jr. possibly next ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target to $119.00. Discover outperforming stocks and invest ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans ... describing in a presentation how he sees 2025 in “two dimensions.” On one hand, Boerner ...

In extending patent protection for its primary cancer medication, Keytruda, Merck (NYSE:MRK) intends to introduce a subcutaneous form of it this year. It's important to also note that Merck is ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...